Year: 2025

Clinical Data doubles known genetic factors associated with urate and Gout CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, highlights recent peer-reviewed, independent, published research reports that expand current knowledge that genetic factors are linked to the over-expression of xanthine oxidase (“XO”), high chronic uric acid concentrations in the blood and gout. These ground breaking findings further support the Company’s approach to treating gout, kidney and other diseases by inhibiting XO. Historically, high uric acid concentration in the blood has been associated with increased...

VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) — Immutable Holdings Inc. (CBOE Canada: HOLD; OTCQB:IHDLF) (“Immutable Holdings” or the “Corporation”), a publicly-traded blockchain holding company, is pleased to announce the voting results of its Annual General and Special Meeting of Shareholders that was held on December 31, 2025 (the “Meeting”). Election of Directors Each of the nominees for election as directors listed in the Corporation’s management information circular dated November 28, 2025 (the “Circular”) were elected as directors of the Corporation for the ensuing year or until their successors are elected or appointed. Reappointment of Auditors At the Meeting, shareholders also approved the reappointment of Richter LLP as auditors of the Corporation for the ensuing year, as well as the authorization of...

TORONTO, Dec. 31, 2025 (GLOBE NEWSWIRE) — Parkit Enterprise Inc. (“Parkit”) (TSXV: PKT) announced today that certain directors, officers, employees and consultants have been issued an aggregate of 1,371,000 options pursuant to Parkit’s option plan, with each such option being exercisable into one common share at an exercise price of $0.56 at any time on or before the tenth anniversary of its issuance. Each of the options vested on grant. Of the options granted above, 1,025,000 options were granted to directors and officers of Parkit. Parkit is relying on exemptions from the formal valuation and minority approval requirements of Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9, for the issuance of these options, pursuant to Section 5.5(b) (Issuer Not Listed on Specified Markets) and Section 5.7(a) (Fair Market...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) — Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today that it closed the previously announced amended revolving credit facility. The amended senior secured reserve-based revolving credit facility, with Citizens Bank, N.A. as the administrative agent, amends the Company’s existing senior secured reserve-based revolving credit facility and extends the maturity to December 31, 2028. The initial borrowing base under the amended revolving credit facility is $25 million with elected commitments of $15 million. The borrowing base will be redetermined on a semi-annual basis with the next redetermination expected to occur in the second quarter of 2026. After closing the amendment on December 31, 2025, Amplify had no balance drawn on the revolving credit facility...

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it entered into a securities purchase agreement with two healthcare focused institutional investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock and Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of common stock, at a combined purchase price of $4.35 per share of common stock (or pre-funded warrant) and associated Series K-1warrants and Series K-2 warrants, for expected gross proceeds to INBS...

USD 100 million senior term loan facility with a 2-year maturity Strengthens liquidity to support execution across Alvotech’s R&D pipeline and global product launches through 2026 Led by GoldenTree Asset ManagementREYKJAVIK, Iceland, Dec. 31, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a USD 100 million senior term loan facility with maturity in December 2027 aimed at strengthening liquidity and supporting the execution of Alvotech’s strategic priorities in 2026. “This USD 100 million financing underscores the long-term commitment of our financing partners at GoldenTree and their alignment with Alvotech’s strategy,” said Robert Wessman, Chairman and CEO of Alvotech. “Their...

USD 100 million senior term loan facility with a 2-year maturity Strengthens liquidity to support execution across Alvotech’s R&D pipeline and global product launches through 2026 Led by GoldenTree Asset ManagementREYKJAVIK, ICELAND (December 31, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a USD 100 million senior term loan facility with maturity in December 2027 aimed at strengthening liquidity and supporting the execution of Alvotech’s strategic priorities in 2026. “This USD 100 million financing underscores the long-term commitment of our financing partners at GoldenTree and their alignment with Alvotech’s strategy,” said Robert Wessman, Chairman and CEO of Alvotech. “Their support strengthens...